FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100513312> ?p ?o ?g. }

• W3100513312 abstract "Background IMC-001 is a fully human IgG1 monoclonal antibody that binds to human PD-L1 and mediate the antibody-dependent cell-mediated cytotoxicity. The main objectives of this study were to evaluate the safety, pharmacokinetics, and pharmacodynamics of IMC-001 in patients with advanced solid tumors. Here, we report final result of the phase 1 study of IMC-001. Methods This open-labeled phase 1 study used standard 3+3 dose-escalation design, dose ranging from 2 to 20 mg. IMC-001 was administered intravenously every two weeks until disease progression or unacceptable toxicity. Dose limiting toxicity (DLT) window was defined as 21 days from the first dose. Adverse events (AEs) were assessed using CTCAE v4.03, and tumor response was assessed by and the Response Evaluation Criteria In Solid Tumors (RECIST) version v1.1. Results Fifteen subjects (8 Male, 7 Female; Median age : 58 [range 39–69]) were included in 5 dose escalation cohorts. No DLT was observed and the maximum tolerated dose was not reached. Most common AEs were general weakness, decreased appetite, fever, and cough. No Grade 4 or 5 treatment emergent AEs (TEAEs) were reported during the study and no TEAE or serious AE led to treatment discontinuation or death. There were no infusion-related reactions during this study. Grade 2 immune-induced thyroiditis and diabetes mellitus suspected to be related to IMC-001 were seen in one subject at 2 mg/kg cohort. Over the dose range of 2 to 20 mg/kg IMC-001, AUC 0-14d, AUC 0—∞, and Cmax generally appeared to increase in a dose proportional manner for each step of dose escalation. Of the 15 enrolled patients, one subject with colon cancer showed partial response, and disease control rate was 33.3%. There were total 3 biliary tract cancer patients (1 GB cancer, 2 Cholangiocarcinoma) who received ≥3 lines of systemic therapies prior to this trial. They all had stable disease during IMC-001 treatment, and one cholangiocarcinoma subject received the treatment for 434 days. Conclusions IMC-001 demonstrated a favorable safety profile up to 20 mg/kg given IV every 2 weeks and showed encouraging preliminary efficacy in patients with advanced solid tumors. Based on PK and PD data, 20 mg/kg was selected as recommended Phase 2 dose (RP2D). Ethics Approval This study was approved by Institutional Review Board; approval number SMC 2018-01-007-001 and H-1801-042-913." @default.
• W3100513312 created "2020-11-23" @default.
• W3100513312 creator A5005933314 @default.
• W3100513312 creator A5007089296 @default.
• W3100513312 creator A5019406140 @default.
• W3100513312 creator A5036242994 @default.
• W3100513312 creator A5044808739 @default.
• W3100513312 creator A5046467729 @default.
• W3100513312 creator A5058521062 @default.
• W3100513312 creator A5059766169 @default.
• W3100513312 creator A5065244228 @default.
• W3100513312 creator A5080295544 @default.
• W3100513312 date "2020-11-01" @default.
• W3100513312 modified "2023-10-16" @default.
• W3100513312 title "288 A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors" @default.
• W3100513312 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0288" @default.
• W3100513312 hasPublicationYear "2020" @default.
• W3100513312 type Work @default.
• W3100513312 sameAs 3100513312 @default.
• W3100513312 citedByCount "0" @default.
• W3100513312 crossrefType "journal-article" @default.
• W3100513312 hasAuthorship W3100513312A5005933314 @default.
• W3100513312 hasAuthorship W3100513312A5007089296 @default.
• W3100513312 hasAuthorship W3100513312A5019406140 @default.
• W3100513312 hasAuthorship W3100513312A5036242994 @default.
• W3100513312 hasAuthorship W3100513312A5044808739 @default.
• W3100513312 hasAuthorship W3100513312A5046467729 @default.
• W3100513312 hasAuthorship W3100513312A5058521062 @default.
• W3100513312 hasAuthorship W3100513312A5059766169 @default.
• W3100513312 hasAuthorship W3100513312A5065244228 @default.
• W3100513312 hasAuthorship W3100513312A5080295544 @default.
• W3100513312 hasConcept C111113717 @default.
• W3100513312 hasConcept C112705442 @default.
• W3100513312 hasConcept C126322002 @default.
• W3100513312 hasConcept C143998085 @default.
• W3100513312 hasConcept C197934379 @default.
• W3100513312 hasConcept C2778715236 @default.
• W3100513312 hasConcept C2779984678 @default.
• W3100513312 hasConcept C29730261 @default.
• W3100513312 hasConcept C31760486 @default.
• W3100513312 hasConcept C71924100 @default.
• W3100513312 hasConcept C90924648 @default.
• W3100513312 hasConcept C98274493 @default.
• W3100513312 hasConceptScore W3100513312C111113717 @default.
• W3100513312 hasConceptScore W3100513312C112705442 @default.
• W3100513312 hasConceptScore W3100513312C126322002 @default.
• W3100513312 hasConceptScore W3100513312C143998085 @default.
• W3100513312 hasConceptScore W3100513312C197934379 @default.
• W3100513312 hasConceptScore W3100513312C2778715236 @default.
• W3100513312 hasConceptScore W3100513312C2779984678 @default.
• W3100513312 hasConceptScore W3100513312C29730261 @default.
• W3100513312 hasConceptScore W3100513312C31760486 @default.
• W3100513312 hasConceptScore W3100513312C71924100 @default.
• W3100513312 hasConceptScore W3100513312C90924648 @default.
• W3100513312 hasConceptScore W3100513312C98274493 @default.
• W3100513312 hasLocation W31005133121 @default.
• W3100513312 hasOpenAccess W3100513312 @default.
• W3100513312 hasPrimaryLocation W31005133121 @default.
• W3100513312 hasRelatedWork W10386318 @default.
• W3100513312 hasRelatedWork W11032860 @default.
• W3100513312 hasRelatedWork W11062511 @default.
• W3100513312 hasRelatedWork W12110721 @default.
• W3100513312 hasRelatedWork W15036479 @default.
• W3100513312 hasRelatedWork W17395675 @default.
• W3100513312 hasRelatedWork W1816852 @default.
• W3100513312 hasRelatedWork W4081904 @default.
• W3100513312 hasRelatedWork W4522418 @default.
• W3100513312 hasRelatedWork W9130807 @default.
• W3100513312 isParatext "false" @default.
• W3100513312 isRetracted "false" @default.
• W3100513312 magId "3100513312" @default.
• W3100513312 workType "article" @default.